Open AccessEffectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial
Author(s) -
Yuanyuan Qin,
Yihong Zhou,
Yanqiu Lu,
Feng Sun,
Sen Yang,
Vijay Harypursat,
Yao-Kai Chen
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000000791
Subject(s) - medicine , outbreak , coronavirus , clinical endpoint , adverse effect , randomized controlled trial , glucocorticoid , incidence (geometry) , clinical trial , methylprednisolone , disease , intensive care medicine , pediatrics , covid-19 , infectious disease (medical specialty) , virology , physics , optics
At the end of 2019, a novel coronavirus outbreak causative organism has been subsequently designated the 2019 novel coronavirus (2019-nCoV). The effectiveness of adjunctive glucocorticoid therapy in the management of 2019-nCoV-infected patients with severe lower respiratory tract infections is not clear, and warrants further investigation.